SCHEMBL694145

SCHEMBL694145

CNc1cccc(C(=O)OC)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.66
NPC1 O15118 3/20 0.66
POLB P06746 1/20 0.65
ALDH1A1 P00352 2/20 0.63
MAPT P10636 4/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
TP53 P04637 1/20 0.58
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
TSHR P16473 1/20 0.55
TCF4 P15884 2/20 0.55
CTNNB1 P35222 2/20 0.55
HTT P42858 1/20 0.55
LOXL2 Q9Y4K0 1/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30444499 1.00 RAB9A (0.66) RAB9ANPC1POLBALDH1A1MAPT
Hydrochloric Acid SCHEMBL1302781 0.98 RAB9A (0.64) RAB9ANPC1POLBALDH1A1MAPT
SCHEMBL28683410 0.85 RAB9A (0.50) RAB9ANPC1POLBALDH1A1MAPT
SCHEMBL19647678 0.85 RAB9A (0.65) RAB9ANPC1POLBALDH1A1MAPT
SCHEMBL13808968 0.85 RAB9A (0.65) RAB9ANPC1POLBALDH1A1MAPT
SCHEMBL22537503 0.84 SMN1; SMN2 (0.59) RAB9ANPC1POLBALDH1A1MAPT
SCHEMBL34953 0.83 TSHR (0.70) RAB9ANPC1POLBALDH1A1MAPT
SCHEMBL16983705 0.83 RAB9A (0.63) RAB9ANPC1POLBALDH1A1MAPT
SCHEMBL28221717 0.83 RAB9A (0.63) RAB9ANPC1POLBALDH1A1MAPT
SCHEMBL28233648 0.83 RAB9A (0.63) RAB9ANPC1POLBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-12479807-B2 Methods using HDAC11 inhibitors VALO HEALTH, INC. (US) 2025-11-25 US disclosed
US-12195472-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2025-01-14 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
US-12144816-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2024-11-19 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 CN disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
US-20010014683-A1 Analgesics; side effect reduction ITO FUMITAKA (JP) 2001-08-16 US disclosed
US-20010011091-A1 Analgesics ITO FUMITAKA (JP) 2001-08-02 US disclosed
US-20010009921-A1 Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor ITO FUMITAKA (JP) 2001-07-26 US disclosed
US-20010008890-A1 Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease ITO FUMITAKA (JP) 2001-07-19 US disclosed
US-6201007-B1 OPIOID KAPPA RECEPTOR AGONISTS; ANALGESICS, ANESTHETICS, NEUROPROTECTIVE AND ANTIINFLAMMATORY AGENTS; STROKES, GASTROINTESTINAL DISORDERS PFIZER INC. 2001-03-13 US disclosed
EP-0934264-A1 PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS PFIZER INC. (US) 1999-08-11 EP disclosed
WO-1998012177-A1 PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS PFIZER INC. (JP) 1998-03-26 WO disclosed
US-5315035-A Hydrogen peroxide detection BOEHRINGER MANNHEIM GMBH (DE) 1994-05-24 US disclosed
US-5084382-A A color former with an oxidizable coupler for detection of hydrogen peroxide or hydrogen peroxide forming system or peroxidase or oxidizers for amine detection BOEHRINGER MANNHEIM GMBH (DE) 1992-01-28 US disclosed
US-4820632-A ANILINE DERIVATIVE AND OXIDIZABLE COUPLER COLORED COMPOUND FOR DETECTION OF HYDROGEN PEROXIDE; MEDICAL DIAGNOSIS BOEHRINGER MANNHEIM GMBH (DE) 1989-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK RAB9A 1568/4885NPC1 991/4885POLB 3027/4885
US-20010009921-A1 Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor OPRL1, OPRD1, OPRK1 RAB9A 4821/4885NPC1 2290/4885POLB 2910/4885
US-20010011091-A1 Analgesics OPRL1, OPRK1, OPRD1 RAB9A 4425/4885NPC1 2239/4885POLB 2807/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK RAB9A 1568/4885NPC1 991/4885POLB 3027/4885
US-12144816-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL9 RAB9A 2887/4885NPC1 2467/4885POLB 2458/4885
US-12479807-B2 Methods using HDAC11 inhibitors HDAC11, HDAC1, HDAC10 RAB9A 3010/4885NPC1 460/4885POLB 175/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK RAB9A 1568/4885NPC1 991/4885POLB 3027/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK RAB9A 1568/4885NPC1 991/4885POLB 3027/4885
US-12195472-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL3 RAB9A 3796/4885NPC1 2000/4885POLB 2896/4885
US-20010014683-A1 Analgesics; side effect reduction OPRL1, OPRK1, OPRD1 RAB9A 4339/4885NPC1 2004/4885POLB 1996/4885
US-20010008890-A1 Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease OPRL1, NAP1L1, OPRK1 RAB9A 4394/4885NPC1 1670/4885POLB 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.